References:

Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-1446.
Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-1438.
Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-517.
Data on file (MYO-026-1207) and Data on file (MYO-034-0608). Malvern, PA: Solstice Neurosciences, Inc; 2007 and 2008.
FDA approval letter. Myobloc for cervical dystonia. December 8, 2000.
FDA approval letter. Botox for cervical dystonia. December 21, 2000.
Heavner J, Leong M, Royal M. The MIND registry: an observational database of patients treated with botulinum toxin type B (Myobloc^®) – pain subset of the database [abstract]. International Conference-Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; June 23-25, 2005; Denver, CO.
Myobloc [package insert]. Malvern, PA: Solstice Neurosciences, Inc; 2004.
Lew MF, Factor SA. Botulinum toxin type B (MYOBLOC) is well-tolerated and efficacious in a long-term observational study: results of an open-label extension trial of repeated dosing in subjects with cervical dystonia. Poster presented at: 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, CA.
Data on file (MYO-031-0108). Malvern, PA: Solstice Neurosciences, Inc; 2007.
Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:211-237.
Comella CL, Jankovic J, Shannon KM, et al; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423-1429.
Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005;20(9):1152-1160.
Consky ES, Basinki A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability.Neurology. 1990;40(suppl 1):445.
Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13(4):227-236.
Data on file (MYO-030-1207). Malvern, PA: Solstice Neurosciences, Inc; 2007.
Data on file (MYO-004-0306). Malvern, PA: Solstice Neurosciences, Inc; 2007.
Data on file (MYO-032-0108). Malvern, PA: Solstice Neurosciences, Inc; 2007.
Data on file (MYO-020-0707). Malvern, PA: Solstice Neurosciences, Inc; 2007.
Camfield L, Ben-Shlomo Y,Warner TT; Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord. 2002;17(4):838-841.
Lew MF. Botulinum toxin type B: an effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskeletal Rehabil. 2002;16:3-9.
Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119-126.

See Important Safety Information below.

An online professional educational program for HCPs who diagnose and treat neck pain associated with cervical dystonia.

Important Safety Information

Myobloc^® (Botulinum Toxin Type B) Injectable Solution is indicated for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Before administering MYOBLOC, physicians should consult the full Prescribing Information.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. These adverse events are generally mild to moderate, transient, self-resolving, and more common with higher doses. Dysphagia is commonly reported with all botulinum toxins in cervical dystonia patients.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (eg, amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (eg, motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Click here for Important Safety Information and full Prescribing Information

Myobloc University | Important Safety Information | Prescribing Information
Terms of Use | Privacy Policy | References